Physician profile
David Schaeffer
NPI 1619403508
$44,517.84
in general payments reported to CMS, 2019-2025
15 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,933 · 2020: $94.81 · 2021: $55.83 · 2022: $12K · 2023: $17K · 2024: $11K · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,917 · Consulting Fee: $5,890 · Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,795.00 |
| Travel and Lodging | $5,916.69 |
| Consulting Fee | $5,890.00 |
| Food and Beverage | $2,644.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $41,498.08 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,894.07 | 2019-2025 | Total30, Precision7, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $297.30 | 2019-2021 | |
| Oyster Point Pharma, INC. | $223.72 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $183.91 | 2023-2025 | Miebo, Infuse, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $109.18 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $94.53 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $39.82 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $38.73 | 2020-2022 | |
| Shire North American Group INC | $30.43 | 2019 | |
| Harrow Eye, LLC | $27.99 | 2025 | Vevye |
| Abbvie INC. | $27.95 | 2022 | |
| Biotissue Holdings INC. | $21.10 | 2022 | |
| Carl Zeiss Meditec, INC. | $16.34 | 2019 | |
| Allergan, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.